Home » Newsletters » BioWorld

BioWorld

Feb. 24, 1993

View Archived Issues

INVESTOR EXERCISES BTGC WARRANTS

DEKALB RELEASING NEW PRODUCTS

HEMACARE LICENSES AIDS TREATMENT METHOD

FUJISAWA FILES IND FOR AMBISOME

ALL QUIET ON THE TRADING FRONT

SPECTRAL TO EVALUATE CDNA CLONES

EARLY SUCCESS IN PRETARGETING TUMORS

BELMAC COMPLETES PHASE I TRIALS

BIOCRYST AWARDED FIFTH PATENT

RESEARCHERS TRY TO GROW FETAL CELLS

ALPHA-1 REVISES TERMS OF WARRANTS

AT SUPPLIES COMPONENTS FOR TESTING KITS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...